Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ASCO Endorses Small-Cell Lung Cancer Guidelines

Updates 2013 Guidelines

Publish date:: September 22, 2015

The American Society of Clinical Oncology endorses these 2013 American College of Chest Physicians guidelines on treatment of patients with small-cell lung cancer (SCLC), with the addition of qualifying statements:

• Surgery is indicated for selected stage I SCLC.

• Limited-stage disease should be treated with concurrent chemoradiotherapy in patients with good performance status.

• Thoracic radiotherapy should be administered early in the course of treatment, preferably beginning with cycle one or two of chemotherapy.

• Chemotherapy should consist of four cycles of a platinum agent and etoposide.

• Extensive-stage disease should be treated primarily with chemotherapy consisting of a platinum agent plus etoposide or irinotecan.

• Prophylactic cranial irradiation prolongs survival in patients with limited-stage disease who achieve a complete or partial response to initial therapy and may do so in similarly responding patients with extensive-stage disease as well.

Citation: Rudin CM, Ismaila N, Hann CL, et al. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. [Published online ahead of print September 8, 2015]. J Clin Oncol. doi:10.1200/JCO.2015.63.7918.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,